Professional considerations for providing mifepristone-induced abortion.
Primary care clinicians who provide comprehensive reproductive heath care can now offer patients mifepristone (Mifeprex) as an abortifacient option. Clinicians, however, must first determine if the state in which they practice has regulations specifying who can perform abortions and dispense drugs, and they must consider clinical office zoning ordinances, staffing, public relations issues, and reimbursement. This article discusses the pharmacology of mifepristone and misoprostol, professional considerations, and how to prevent and manage adverse effects and complications of medical abortion.
Fielding
S L
SL
Reproductive Health Program, University of Rochester, Rochester, N.Y., USA.
Lee
S S
SS
Schaff
E A
EA
D000021:Abortifacient Agents, Steroidal; D000028:Abortion, Induced / Q000009:adverse effects / Q000331:legislation & jurisprudence* / Q000379:methods* / Q000451:nursing; D002985:Clinical Protocols; D011307:Drug Prescriptions; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D015735:Mifepristone; D009722:Nurse Practitioners / Q000193:education / Q000458:organization & administration*; D011320:Primary Health Care / Q000458:organization & administration* / Q000592:standards*; D017009:Professional Autonomy; D012051:Reimbursement Mechanisms / Q000331:legislation & jurisprudence; D014481:United States
D000021:Abortifacient Agents, Steroidal; D015735:Mifepristone